文献速递血栓与止血

靶向血管性血友病因子治疗肝病:一种新策略?

Targeting von Willebrand factor in liver diseases: A novel therapeutic strategy?
PubMed 文献 · J Thromb Haemost · 2021-05-03

临床与实验证据支持VWF功能与肝病进展相关,靶向VWF可能成为肝病创新疗法。

要点

  • VWF升高可能加速肝内血栓形成并驱动肝病进展。
  • 靶向VWF有望在低出血风险下减少肝内血栓。

核心结论

  • 临床与实验证据支持VWF功能与急慢性肝病进展相关,靶向VWF可能成为肝病创新疗法。

研究设计与样本

  • 综述,聚焦VWF功能与急慢性肝病进展关联的临床和实验证据。

主要发现

  • 高度升高的VWF被提出可加速肝内血栓形成,从而驱动疾病进展。
  • 抗凝药延缓肝病进展的疗效部分归因于减少肝内微血栓形成。

临床怎么用

  • 靶向VWF可能作为肝病患者减少肝内血栓且出血风险最小的创新治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute and chronic liver disease are associated with substantial alterations in the hemostatic system. Evidence from both experimental and clinical studies suggests that anticoagulants slow the progression of liver disease. Efficacy of those anticoagulant drugs is, in part, attributed to a reduction of microthrombi formation within the liver. Although anticoagulant drugs show promising results, bleeding risk associated with these drugs is an obvious drawback, particularly in patients with a complex coagulopathy driven by decreased liver function. Identifying therapies that reduce intrahepatic thrombosis with minimal bleeding risk would significantly advance the field. Among the hemostatic alterations observed in patients are substantially increased levels of the platelet-adhesive protein von Willebrand factor (VWF). In contrast, levels of A Disintegrin and Metalloproteinase with Thrombospondin motifs, the enzyme that regulates VWF activity, are significantly reduced in patients with liver disease. Highly elevated VWF levels are proposed to accelerate intrahepatic thrombus formation and thus be a driver of disease progression. Strong clinical evidence suggesting a link between liver disease and changes in VWF is now being matched by emerging mechanistic data showing a detrimental role for VWF in the progression of liver disease. This review focuses on clinical and experimental evidence supporting a connection between VWF function and the progression of acute and chronic liver diseases. Furthermore, with the recent anticipated approval of several novel therapies targeting VWF, we discuss potential strategies and benefits of targeting VWF as an innovative therapy for patients with liver disease.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Groeneveld DJ, Poole LG, Luyendyk JP, et al. Targeting von Willebrand factor in liver diseases: A novel therapeutic strategy? J Thromb Haemost. 2021. PMID: 33774926. doi:10.1111/jth.15312

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。